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**ABSTRACT**

**Objective:** This post hoc analysis evaluated metabolic syndrome occurrence during long-term treatment of schizophrenia with lurasidone or other antipsychotic agents.

**Methods:** Metabolic syndrome rates (as defined by the US National Cholesterol Education Program-Adult Treatment Panel III without using drug treatment criteria) were evaluated in adult patients with schizophrenia treated with lurasidone in 2 long-term, active-controlled studies (quetiapine XR or risperidone). In the quetiapine XR--controlled study, patients completing a 6-week, double-blind, placebo-controlled, fixed-dose trial of lurasidone (80 mg/d or 160 mg/d) or quetiapine XR (600 mg/d) continued on double-blind, flexibly dosed lurasidone (40--160 mg/d) or quetiapine XR (200--800 mg/d) for up to 12 months. In the risperidone-controlled study, patients received double-blind, flexibly dosed lurasidone (40--120 mg/d) or risperidone (2--6 mg/d) for up to 12 months.

**Results:** Among patients without metabolic syndrome at baseline in the quetiapine XR--controlled study, 2.4% (2/84) of patients treated with lurasidone and 7.4% (2/27) of patients treated with quetiapine XR developed metabolic syndrome at month 12; risk for developing metabolic syndrome was not significantly different between treatment groups (odds ratio=0.305; 95% CI, 0.041, 2.277; *P*=NS). Of patients without metabolic syndrome at baseline in the risperidone-controlled study, 10.3% (12/117) of patients treated with lurasidone and 23.2% (16/69) of patients treated with risperidone developed metabolic syndrome at month 12; risk for developing metabolic syndrome was significantly lower for lurasidone-treated versus risperidone treated patients (odds ratio=0.379; 95% CI, 0.167, 0.858; *P*=0.02).

**Conclusions:** In this post-hoc analysis, long-term treatment with lurasidone was associated with significantly lower rates of metabolic syndrome in patients with schizophrenia compared with treatment with risperidone; metabolic syndrome rates were numerically lower (but not significantly different) for lurasidone compared with quetiapine XR.
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